Ketamine Infusions for PTSD and Treatment-Resistant Depression
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02577250|
Recruitment Status : Unknown
Verified October 2015 by Cristina Sophia Albott, Minneapolis Veterans Affairs Medical Center.
Recruitment status was: Recruiting
First Posted : October 16, 2015
Last Update Posted : October 16, 2015
|Condition or disease||Intervention/treatment||Phase|
|Depressive Disorder, Treatment-Resistant Stress Disorders, Post-Traumatic||Drug: Ketamine||Phase 1|
The proposed study is a pilot study designed to determine the efficacy and safety of serial ketamine infusions among veterans with treatment-resistant depression (TRD) as well as chronic post-traumatic stress disorder (PTSD). The investigators hypothesize that six infusions of ketamine will be effective in decreasing severity of depressive symptoms and maintaining response.
Participants will be male/female veterans (18 to 75 years old) of any era or military background who suffer from TRD and chronic PTSD. Potential participants will be recruited from Mental Health clinics and screened for eligibility using a two stage process (phone/chart review, followed by interview). Participants will receive six ketamine infusions on a Monday-Wednesday-Friday schedule over 2 weeks. On the day of infusion, participants will be required to stay at the clinical site for 3 hours after the medication has been given. Follow-up visits will occur at different time points over the course of 2 months after the two week infusion period has been completed.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Efficacy and Safety of Repeated Intravenous Subanesthetic Ketamine Infusions Among Veterans With Treatment Resistant Depression Comorbid With Chronic Post-Traumatic Stress Disorder: A Proof-of-concept Study|
|Study Start Date :||May 2015|
|Estimated Primary Completion Date :||February 2016|
|Estimated Study Completion Date :||May 2016|
Experimental: Six ketamine infusions
Six infusions of 0.5 mg/kg ketamine hydrochloride solution over 2 weeks.
Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.
- Montgomery-Asberg Depression Rating Scale (MADRS) [ Time Frame: 24 hours post-infusion ]
- Clinical-Administered PTSD Scale (CAPS) [ Time Frame: 2 weeks after the first infusion ]
- Montgomery-Asberg Depression Rating Scale (MADRS) [ Time Frame: up to 2 months ]
- PTSD Checklist [ Time Frame: 24 hours post-infusion ]
- Clinical-Administered PTSD Scale (CAPS) [ Time Frame: up to 2 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02577250
|Contact: Tegan Carr||612-467-2974||Tegan.Carr@va.gov|
|United States, Minnesota|
|Minneapolis Va Health Care System, Minneapolis MN||Recruiting|
|Minneapolis, Minnesota, United States, 55417|
|Contact: Tegan Carr 612-467-2974 Tegan.Carr@va.gov|
|Contact: Cristina S Albott, MD, MA Cristina.Albott@va.gov|
|Principal Investigator: Cristina S Albott, MD,MA|
|Principal Investigator: Paulo Shiroma, MD|
|Principal Investigator:||Paulo Shiroma, MD||Minneapolis Veterans Affairs Medical Center|
|Principal Investigator:||Cristina S Albott, MD,MA||Minneapolis Veterans Affairs Medical Center|